Screening newborns for cystic fibrosis (CF) is considered to be an ethical undertaking in regions with a significant incidence of the condition. Current screening protocols result in recognition of infants with an equivocal diagnosis. A survey of European practice suggested inconsistencies in the evaluation and management of these infants.
Introduction
There is a good agreement that screening newborns for cystic fibrosis (CF) is a valid and ethical undertaking in regions such as Europe with a significant incidence of the condition [1] . Protocols for screening rely on the recognition that infants with CF have a high level of immuno-reactive trypsinogen (IRT) in their blood in the first week of life [2] . This test is sensitive but has poor specificity and therefore a second tier of investigations is necessary to identify those infants most at risk of CF [3] . In most newborn screening (NBS) protocols, this involves examining for common mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene which are associated with CF [4] . Such protocols will result in the recognition of carrier infants and data from well-established NBS programmes suggest that more carriers are recognised by NBS than might be expected for the incidence of CF in that population [5] . It has been concluded that this reflects the fact that carriers have a higher IRT than the non-carrier population and this is supported by data from population studies [6] . In most NBS protocols infants recognised as putative carriers have further assessment including a sweat test to exclude CF [4] .
Another significant challenge of NBS for CF is the recognition of infants with an equivocal diagnosis [4, 7] . This reflects the heterogeneous nature of the condition and poses a challenge to CF teams. Infants with one recognised CFTR mutation or persistent hypertrypsinaemia may have an intermediate sweat test result or an infant may be recognised with two CFTR mutations, one or both of which have unclear phenotypic consequences [7] . There is significant variability in the evaluation and management of these infants with an equivocal diagnosis [3, 8] . We have used a modified Delphi method to form a consensus on the evaluation and management of these infants [9] . The Delphi method is a recognised technique that provides a formal strategy to gather expert opinion and form a consensus when there is a lack of high quality evidence on which to base practice. The method facilitates the inclusion of experts from a geographically disperse region and establishes a framework which makes it possible to clearly trace back how the group came to a decision.
Methods
Twenty-one preliminary statements were composed by a core group of experts in the field (CC, AM and KWS), taking into account the results of a survey of European practice [4] . The statements covered four thematic areas; sweat testing, further assessments and investigations, review arrangements and database. Two European Cystic Fibrosis Society (ECFS) working groups (the Diagnostic Network (ECFDN) and the Neonatal Screening Working Group) were approached and their members, which include clinicians, biochemists and geneticists, contacted by email. Additional invitations were made to increase multidisciplinary input. Consensus was determined a priori to be 80% of ratings providing agreement with the statement (considered sufficient for this type of study) [9] .
For round one, specialists were asked to rate their opinion of each statement by choosing one of three options; 1) agree, 2) could agree if reworded or 3) disagree. Specialists choosing options 2) or 3) were asked for comments and also suggestions for alternative or modified statements.
After round one, statements not achieving consensus (or achieving consensus with provisos) were modified by the core group, taking into account the comments and suggestions made by respondents. These modified statements were then circulated in round two together with the original statements, the group ratings from round one and a summary of comments. Individuals who replied to round one were included in round two.
Following round two, statements not achieving consensus were presented and discussed in the European Cystic Fibrosis Neonatal Screening Working Group meeting at the 30th European Cystic Fibrosis Society Conference, Belek, Turkey in 2007. This meeting involved members of the consensus group (although not all) and other CF Specialists. The entire consensus document was presented, but the focus of the meeting was on statements that had not achieved consensus. This facilitated an open discussion that enabled deeper reflection on the issues around these statements. Statements were subsequently revised by the core group taking into account the discussions at this meeting and comments already received from round two. The revised statements were again circulated in round three to all respondents together with the original statements, the level of agreement from round two and respondents' comments ( Fig. 1) . Four appendices were constructed to provide further information and background to the statements (Table 1) 
Results

Round one
Forty-one responses from specialists in 11 European countries were received for round one. A consensus of over 80% was achieved on twelve of 21 statements. A further five statements were approaching consensus with greater than 60% agreement. Four statements had poor level of agreement (b60%).
Round two
Nine statements not achieving consensus in round one and three that did with provisos were revised by the core group, following analysis of respondents' comments. Respondents were asked to rate their agreement with both the revised and modified statements. Thirty-eight responses were obtained following round two. A consensus of greater than 80% was achieved on a further ten statements. Consensus was not achieved in two.
Round three
The two statements not achieving consensus were discussed at the ECFS Screening Working Group Meeting. Taking into account this meeting and respondents comments, it was clear that modification and combination of four statements were required to obtain consensus, reducing the number of statements from twenty one to nineteen. Thirty-four responses were obtained to round three and consensus was achieved on all nineteen statements (Table 1 ). An algorithm was developed from the consensus statements (Fig. 2) . Seven specialists who responded to round one did not respond to round three (17% attrition rate).
Specific issues and comments
Clinic size
Original statements for round one defined specialist CF clinic size greater than 100 patients and achieved consensus. Despite this, several respondents discussed the size of clinics (N50 or N 100 patients) citing concerns that in some areas of Europe specialist CF clinics are traditionally smaller. Overall however it was felt beneficial to include a proposed number and the statements were modified to "specialist CF clinic (with N50 patients)", which again achieved consensus.
Sweat test
The sweat testing experience of the centre was suggested at greater than 150 sweat tests performed annually and this achieved consensus in round one (Statement 3). See also Appendix A.
Equivocal sweat test result
All infants considered by the guideline will have one or more raised IRT. When these infants subsequently have an equivocal sweat test result they require assessment and review in a specialist CF clinic with a repeat sweat test (Statement 1). If the sweat test in an accredited centre remains equivocal (chloride, 30-60 mmol L − 1 ) further investigation is required. This should include extended gene analysis if one or no CFTR mutations have been identified (Statement 5) and baseline assessment for respiratory and non-respiratory disease (Statements 8 and 9). If these infants show any clinical evidence supportive of the diagnosis of CF they should have regular follow up in a specialist CF clinic (Statement 10). If there is no clinical evidence of CF they should be reviewed in a specialist CF clinic with sweat test repeated between 6 and 12 months of age (Statement 13).
What constitutes a negative screening result?
Infants who have equivocal sweat test (chloride 30-60 mmol/l) that on repeat test is found to be normal (b 30mmol/l) do not require further clinical review (Statement 4). This was agreed to be a negative screening result i.e. CF not suspected (85%, round one).
Infants who have one or more raised IRT measurements, one CFTR mutation and a normal sweat test have a negative screening test (Statement 7). This statement was approaching consensus in round one (71%). Following respondents comments, the statement was modified to advise discussion of carrier status and this achieved 92% consensus in round two.
Extended gene analysis
Extended gene analysis is indicated when an infant has had two equivocal sweat test results and only one or no CFTR mutation has been identified on the local common mutation panel (Statement 5, 85% consensus round one) (Appendix B). Extended gene analysis should not be performed in infants with one or more raised IRT, one CFTR mutation and a normal sweat test. These infants have a negative screening result (Statement 6, 80% consensus round one). Further investigations may be indicated as determined by the clinical situation (for example, chest CT scan, and bronchoscopy). 9 Infants with two equivocal sweat tests require detailed baseline assessment for non-respiratory disease (fecal elastase). Other investigations as clinically indicated. 10 Infants with two equivocal sweat tests and any clinical evidence supportive of a CF diagnosis should have regular follow up in a CF specialist clinic ( Appendix C). 11 Infants with two equivocal sweat tests, one or no CF causing mutations and no clinical evidence of CF should be considered for further investigation of a physiological defect in a centre with appropriate experience ( Appendix D). 12 Infants with two equivocal sweat tests, one or no CF causing mutation, no clinical evidence of CF and evidence of ion transport defect on further testing should be followed up in a specialist CF clinic. 13 All infants with two equivocal sweat tests, one or no CF causing mutation, no clinical evidence of CF should be reviewed in a specialist CF clinic with a repeat sweat test at 6-12 months of age. 14 Infants with two CFTR gene changes (as statement 2) but a normal sweat test (at least one performed in a centre with adequate experience, as per statement 3) should have detailed clinical assessment (as 8 and 9). 15 Infants with two CFTR gene changes (as statement 2), a normal sweat test and any clinical evidence of CF should have regular follow up in a CF specialist clinic. 16 Infants with two CFTR gene changes (as statement 2), a normal sweat test and no clinical evidence of CF should be considered for further investigation of a physiological defect in a centre with appropriate experience ( Appendix D). 17 Infants with two CFTR gene changes (as statement 2), a normal sweat test, no clinical evidence of CF but evidence of abnormal ion transport should have regular follow up in a specialist CF clinic. 18 Infants with two CFTR gene changes (as statement 2), a normal sweat test and no clinical evidence of CF should be reviewed in a specialist CF clinic with a repeat sweat test at 6-12 months. 19 Clinical and demographic information on all infants with an equivocal diagnosis should be entered onto a database or registry (pending consent from legal guardian).
3.4.6. Baseline assessment for respiratory and non-respiratory disease It was agreed that infants who had two equivocal sweat test results or who have two CFTR gene changes and a normal sweat test should have baseline clinical assessment (Statements 8, 9 and 14). In round one, baseline assessment for respiratory disease included CT scan and bronchoscopy and this statement achieved a poor level of agreement (41%). The statement was modified to include these investigations only when indicated by the clinical situation and 89% agreement was achieved in the second round (Statement 8). Similarly a significant number felt that some of the proposed non-respiratory investigations were unnecessary and this statement was changed accordingly (to faecal elastase with other investigations as clinically indicated). The statement achieved 92% agreement in round two (Statement 9).
Further investigation of physiological defect
A number of measurements of transepithelial salt transport exist that may help in investigating an equivocal diagnosis of CF. However, none have the face validity of sweat electrolyte measurement and are essentially extensions of research methodology. This was reflected in the variability of responses to statements concerning further electrophysiological investigation ranging from enthusiastic advocates to confirmed sceptics. It was agreed with 83% consensus in round two that infants who had two equivocal sweat tests and no clinical evidence of CF should be considered for further investigation of a physiological defect (Statement 11). If there is evidence of ion transport defect even in the absence of clinical evidence of CF with only one CFTR mutation these infants should be followed up in a specialist CF clinic (Statement 12).
It proved difficult to obtain a consensus regarding the subsequent management of infants who had no evidence of ion transport defect. In the absence of consensus, these infants are covered by Statement 13. This reflects a general anxiety that it would be inappropriate to exclude a diagnosis of CF on the basis of these measures alone, even when there is no clinical suspicion following baseline assessment. Table 1 ) that corresponds to that part of the pathway. An important point to note is that infants who enter the pathway with an equivocal sweat test and then have a normal repeat sweat test do not require extended gene analysis or further clinical review (although some may require advice regarding carrier status). Clinical assessment for evidence of CF is considered important with respect to determining subsequent review arrangements (infants with any clinical evidence supporting a CF diagnosis should be seen in a specialist CF clinic). ⁎ One of which has unclear clinical significance. † In a centre with suitable experience (Appendix A).
‡ Normal = sweat Cl b30 mmol l − 1 , equivocal = sweat Cl ≥ 30 and b60 mmol l − 1 , raised = sweat Cl ≥ 60 mmol l − 1 .
Two CFTR gene mutations one or both of which have unclear clinical significance
The term CFTR gene change was used in the statements to highlight that these mutations have unclear phenotypic consequences. Subsequently, an ECFS consensus has been achieved on the use and interpretation of CF mutation analysis in clinical practice and has concluded that the term "mutation" should be used to define any molecular alteration in the DNA sequence of the CFTR gene [10] . Therefore for the purposes of this process the terms CFTR gene change and mutation are interchangeable. The dilemma remains that a number of frequently recognised CFTR gene mutations have unclear phenotypic consequence. The situation in CF NBS is further exacerbated by the fact that some CFTR mutations that are clearly "CF causing" can have little if any phenotypic consequence in the first years of life, related to the confounding impact of environment and other non-CFTR genes.
There was clear agreement that if these infants have any clinical evidence of CF they should have regular follow up in a specialist CF clinic, even with a normal sweat test result (Statement 15). If there is no clinical evidence of CF they should be considered for further investigation of ion transport defect (Statement 16) but regardless should be reviewed in a specialist CF clinic with sweat test repeated between 6 and 12 months of age (Statement 18). If there is evidence of abnormal ion transport these infants should have regular review in a specialist CF clinic (Statement 17).
Discussion
There is a good agreement that screening infants for CF is an ethical undertaking in regions with a significant incidence of the condition [1] . Unfortunately, current NBS protocols result in recognition of infants with an equivocal diagnosis of CF. To some degree this reflects the heterogeneity of the condition and the sensitivity of the IRT measurement. Infants with an equivocal diagnosis fall into two groups; those with intermediate sweat electrolytes (above the level expected for this age group), but no or one recognised CFTR gene mutation and those with two CFTR gene mutations, one or both of which have unclear long term phenotypic consequences.
Using a modified Delphi method, we have produced 19 statements that will act as a guide for CF teams in the evaluation and management of infants with an equivocal diagnosis following newborn screening. Strengths of this process have been the inclusive nature across a wide geographical area and a robust framework that enables clear identification of decision making pathways. From the consensus guideline, we have produced an algorithm to aid clinicians involved in CF NBS programmes. It was not the aim of this group to provide a diagnostic framework; rather to provide a pragmatic guideline for the management and evaluation of these infants. The end-points in the algorithm are therefore functional rather than categorical (Fig. 2) .
Although the majority of statements attained consensus in the early phases of the process, some areas were more challenging. The group meeting was an essential part of the Delphi process to identify issues around these statements and achieve a final consensus. These guidelines can be used in established screening regions and in those with emerging programmes to guide the evaluation and management of this challenging clinical dilemma. Ion transport across airway epithelium can be assessed by measuring the baseline PD. The impact on the PD of perfusing different solutions and drugs provides further information to differentiate CF from non-CF recordings.
The exploring electrode is placed in the nose. A reference electrode is placed either subcutaneously or over abraded skin on the forearm. Solutions are perfused through the exploring electrode into the nose and can be swallowed.
Very few centres are able to undertake this measurement in infants although it is more widely available in older children and adults.
Intestinal Current Measurements (ICM)
A biopsy is mounted in the laboratory in a device (Ussing chamber) that enables measurement of transepithelial ion transport. Various aspects of ion transport can be examined. 
